Ovarian Cancer and Immunotherapy Research (OCiR)

About

Ovarian Cancer and Immunotherapy Research (OCiR) is a subdivision of the Reproductive Research Group that aims to provide high-quality basic and clinical research on ovarian cancer, its detection, diagnosis, prognosis, prevention, and treatment. The research team also works to provide an advanced scientific understanding of all aspects of ovarian tumor immunology and cancer immunotherapy. Our team consists of experienced clinicians, scientists, researchers, and postgraduate students who are highly enthusiastic and passionate about providing new insights into unresolved medical mysteries in the progression of ovarian cancer. We hope that our scientific efforts will be a stepping stone to discover novel therapeutics for the management of ovarian cancer.

Research Unit Members

Profesor Dr. Nirmala @ Chandralega A/P Kampan

Dr. Nor Haslinda Abd Aziz

Profesor Dr. Mohamad Nasir Shafiee

Profesor Madya Dr. Chew Kah Teik

Selected Research Projects

1. Detection of inflammatory and immunosuppressive molecular alteration signatures to prevent disease relapse in women with high-grade serous ovarian cancer (FRGS).
2. Analysis of the transcriptomic profile of monocytes from peripheral blood and ovarian tissue expressing Programmed Death Ligand-1 in women with epithelial ovarian cancer (FRGS).
3. Developing a multi-biomarker signature panel for diagnosis of epithelial ovarian cancer using surface plasmon resonance (SPR) technology and validation with multiplex immunobead assay and single cell sequencing (Geran Universiti).
4. Identifying TP53 and PTEN Protein Expression in High Grade Serous Ovarian Cancer (HGSOC) using Tissue Microarray Method and Its Association with Platinum Sensitivity (Geran Fakulti)
5. The Protein Expression of TNFR2 and STAT3 in High Grade Serous Ovarian Cancer (HGSC) Tissue and Its Association with Platinum Sensitivity (Geran Fakulti)

Selected Research Publications

1. Identifying signature molecular biomarkers in endometrioid and clear cell ovarian carcinoma with underlying endometriosis. Medical Journal of Malaysia, jilid 74, halaman 44. http://www.e-mjm.org/2019/v74s1/GY-39-40.pdf
2. The protein expression of TNFR2 and STAT3 in high-grade serous ovarian cancer (hgsc) tissue and its association with platinum sensitivity. International Journal of Gynecological Cancer, jilid 30, halaman A47. https://doi.org/10.1136/ijgc-2020-IGCS.85
3. Combining TNFR2-expressing TREGS and IL-6 as superior diagnostic biomarkers for high-grade serous ovarian cancer masses. Cancers, jilid 15, halaman 1-20. https://doi.org/10.3390/cancers15030667
4. Clinical Use of Programmed Cell Death1 (PD1) and its Ligand (PDL1) Expression as Discriminatory and Predictive Markers in Ovarian Cancer. Clinical Cancer Research, jilid 23, halaman 3453 – 3460. https://doi.org/1158/1078-0432.CCR-16-2366
5. Predicting prognosis and platinum resistance in ovarian cancer: Role of immunohistochemistry biomarkers International Journal of Molecular Sciences, jilid 24, halaman 1 – 20. https://doi.org/10.3390/ijms24031973
6. New predictive biomarkers for ovarian cancer, Diagnostics, jilid 11, halaman 1 – 20. https://doi.org/3390/diagnostics11030465
7. Recent Advances in Surface Plasmon Resonance (SPR) Technology for Detecting Ovarian Cancer Biomarkers, jilid 15, halaman 5607 – 5633 20. https://doi.org/10.3390/cancers15235607
8. Unlocking ovarian cancer heterogeneity: advancing immunotherapy through single-cell transcriptomics. Frontiers in Oncology, halaman 1 – 16. https://doi.org/3389/fonc.2024.1388663